MHRA Approves Trofolastat: A Breakthrough in Prostate Cancer Imaging
On March 28, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), marking a significant advancement in prostate cancer diagnostics.
On March 28, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), marking a significant advancement in prostate cancer diagnostics.
MHRA Approves Trofolastat: A Breakthrough in Prostate Cancer Imaging
On March 28, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), marking a significant advancement in prostate cancer diagnostics.
thesentinelcurrent.co.uk
March 28, 2025 at 11:29 AM
MHRA Approves Trofolastat: A Breakthrough in Prostate Cancer Imaging
On March 28, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), marking a significant advancement in prostate cancer diagnostics.
On March 28, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), marking a significant advancement in prostate cancer diagnostics.
#cancerdiagnostics #menshealth #nuclearmedicine #MHRAapprovel #prostatecancer #trofolastat #Rotop #99mTcMIP1404 #SPECTimaging #PSMASPECTtracer #RoTecPSMA #PSMA #technetium99m #PSMAtargetingdiagnosticproduct #prostatecancerimaging #prostatecancerdiagnosticpathways
pharmatimes.com/news/mhra-ap...
pharmatimes.com/news/mhra-ap...
MHRA approves prostate cancer imaging agent trofolastat - PharmaTimes
Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK
pharmatimes.com
April 9, 2025 at 11:37 AM
NEWS: The Medicines and Healthcare products Regulatory Agency (#MHRA) in the UK said it has given a world-first approval to #Rotop's trofolastat, a PSMA-targeting agent for detecting lesions in men with #prostatecancer.
UK first to approve Rotop's prostate cancer imaging agent
The UK has given a world-first approval to Rotop's RoTecPSMA, a new imaging agent for detecting lesions in men with prostate cancer.
pharmaphorum.com
April 1, 2025 at 3:07 PM
NEWS: The Medicines and Healthcare products Regulatory Agency (#MHRA) in the UK said it has given a world-first approval to #Rotop's trofolastat, a PSMA-targeting agent for detecting lesions in men with #prostatecancer.